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Abstract
Background: Replacement therapy for hemophilia remains a lifelong treatment. Only gene therapy can cure hemophilia
at a fundamental level. The clustered regularly interspaced short palindromic repeats–CRISPR associated nuclease
9 (CRISPR-Cas9) system is a versatile and convenient genome editing tool which can be applied to gene therapy
for hemophilia.
Methods: A patient’s induced pluripotent stem cells (iPSCs) were generated from their peripheral blood mononuclear
cells (PBMNCs) using episomal vectors. The AAVS1-Cas9-sgRNA plasmid which targets the AAVS1 locus and the AAVS1-
EF1α-F9 cDNA-puromycin donor plasmid were constructed, and they were electroporated into the iPSCs. When insertion
of F9 cDNA into the AAVS1 locus was confirmed, whole genome sequencing (WGS) was carried out to detect
the off-target issue. The iPSCs were then differentiated into hepatocytes, and human factor IX (hFIX) antigen
and activity were measured in the culture supernatant. Finally, the hepatocytes were transplanted into non-
obese diabetic/severe combined immunodeficiency disease (NOD/SCID) mice through splenic injection.
Results: The patient’s iPSCs were generated from PBMNCs. Human full-length F9 cDNA was inserted into the
AAVS1 locus of iPSCs of a hemophilia B patient using the CRISPR-Cas9 system. No off-target mutations were
detected by WGS. The hepatocytes differentiated from the inserted iPSCs could secrete hFIX stably and had
the ability to be transplanted into the NOD/SCID mice in the short term.
Conclusions: PBMNCs are good somatic cell choices for generating iPSCs from hemophilia patients. The iPSC
technique is a good tool for genetic therapy for human hereditary diseases. CRISPR-Cas9 is versatile, convenient, and
safe to be used in iPSCs with low off-target effects. Our research offers new approaches for clinical gene therapy
for hemophilia.
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Background
Hemophilia, caused by mutations of coagulation factors
VIII (F8) and IX (F9), is one of the best-known heredi-
tary hemorrhagic disorders. The current standard treat-
ment is replacement therapy, which is effective but runs
the risk of viral infection, and remains a lifelong treat-
ment. Only gene therapy can cure hemophilia at a fun-
damental level [1]. The relatively small size of the F9
coding sequence (~ 1.5 kb) makes hemophilia B (HB) a
better target for genetic research compared with F8
which causes hemophilia A (HA). Adeno-associated viral
(AAV) vectors are widely used in the gene therapy for
HB. A recent clinical trial indicated that HB patients
retained 1–6% of the normal FIX value over 3 years after
AAV8 vector injection [2], and the trial is still in pro-
gress. However, immune responses to the AAV capsid
limit the wider application of this approach.
In 2013, a versatile and convenient genome editing
tool, the clustered regularly interspaced short palindromic
repeats–CRISPR associated nuclease 9 (CRISPR-Cas9)
system, was introduced [3, 4]. The system robustly cuts
DNA molecules at fixed points through Cas9 endonucle-
ase action in the guide of an engineered single guide RNA
(sgRNA). DNA double-strand breaks (DSB) produced by
Cas9 can be further processed by homology-directed
repair (HDR) and result in precise knock-in of exogenous
genes of interest, thereby achieving overexpression of
these genes. Compared with traditional gene editing tools,
such as zinc finger nucleases (ZFNs) and transcription
activator-like effector nucleases (TALENs), CRISPR-Cas9
is more efficient, much easier to operate, achieves a
homozygous mutant, and can bring multiple mutations in
different sites at the same time [5]. So far, the CRISPR-
Cas9 system has been reported for genome editing in hu-
man, mice, zebra fish, yeast, and bacteria [6–9].
The induced pluripotent stem cell (iPSC) technique is
a significant breakthrough in the stem cell domain in the
twenty-first century [10, 11], which promotes the devel-
opment of regenerative medicine. A prominent advan-
tage of iPSCs is that they are not immunogenic when
used in personalized cellular therapy. The iPSCs come
from a single individual, and are sent back to the same
patient after in-vitro genetic engineering or differenti-
ation, avoiding the problem of immunological rejection.
The AAVS1 locus, a “safe-harbor” site, lying in the first
intron of the PPP1R12C gene on human chromosome 19,
has an open chromosomal region that allows the insertion
of an exogenous gene [12]. Many groups targeted the
AAVS1 locus using ZFN, TALEN, or CRISPR-Cas9 and
described stable transgene expression [3, 13–21]. The
AAVS1 locus is an excellent choice for transgene expres-
sion, so we inserted human full-length F9 cDNA into the
AAVS1 locus of iPSCs of a HB patient using CRISPR-
Cas9 in this study. The edited iPSCs were then induced to
hepatocytes able to secrete human FIX (hFIX), and these
hepatocytes were able to be transplanted into non-obese
diabetic/severe combined immunodeficiency disease
(NOD/SCID) mice in the short term.
Methods
Generation of iPSCs of the HB patient
The patient with HB was clinically and genetically con-
firmed in the Institute of Hematology and Blood Disease
Hospital, Chinese Academy of Medical Sciences, Tianjin,
China. iPSC lines were generated from peripheral blood
mononuclear cells (PBMNCs), using four episomal
vectors, as described previously [22]. PBMNCs were
separated from peripheral venous blood of patients by
the Ficoll-Isopaque method. The reprogramming process
was completed under hypoxic conditions (4% O2). The
four episomal vectors used were supplied by Xiaobing
Zhang from the Department of Medicine at Loma Linda
University, CA, USA.
Karyotype analysis
For karyotype analysis, iPSCs were harvested after 10
passages, according to a general protocol. The slides
were visualized under a microscope and 20 split cells
were selected randomly.
Teratoma formation assay
iPSCs were injected intramuscularly into NOD/SCID
mice. Teratomas formed within 6–8 weeks and har-
vested samples were fixed in 4% paraformaldehyde over-
night. Paraffin sections were stained with hematoxylin
and eosin (H&E) for histological determinations.
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde for 30 min at
room temperature (RT), and blocked with blocking
buffer (PBS + 5% goat serum + 0.3% BSA) for 1 h at RT.
Primary antibodies were incubated overnight at 4 °C.
The cells were then incubated with secondary antibodies
for 1 h at 37 °C. Nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) for 5 min. Descrip-
tions of the primary and secondary antibodies are pre-
sented in Additional file 1: Table S1.
Quantitative real-time PCR
RNA was extracted using the RNeasy Mini kit (Qiagen,
Dusseldorf, Germany) following the manufacturer’s instruc-
tions. RNA was reverse transcribed using a first-strand
cDNA synthesis kit (Life Technologies, Carlsbad, CA,
USA). Quantitative real-time PCR (qRT-PCR) analysis was
performed in triplicate, using a Step-One-Plus Real-Time
PCR system (Applied Biosystems, Foster City, CA, USA).
The cDNA of nontransfected PBMNCs from the patient
was used as negative control, while H1 embryonic stem
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cells were used as positive control. The primer sequences
are presented in Additional file 2: Table S2.
Construction of CRISPR-Cas9 related plasmids
An AAVS1-Cas9-sgRNA plasmid was designed to cut the
human AAVS1 locus; the sgRNA sequence was 5′-
GGGGCCACTAGGGACAGGAT-3′ [3]. Two donor plas-
mids, the AAVS1-CAG-GFP-puromycin donor plasmid
and the AAVS1-EF1α-F9 cDNA-puromycin donor plas-
mid, were designed to insert GFP and F9 cDNA into the
AAVS1 locus, respectively. The AAVS1-Cas9-sgRNA plas-
mid, the AAVS1-CAG-GFP-puromycin donor plasmid,
and the AAVS1-EF1α-puromycin empty plasmid were
bought. We constructed the AAVS1-EF1α-F9 cDNA-
puromycin donor plasmid by inserting human full-length
F9 cDNA into the AAVS1-EF1α-puromycin empty plas-
mid. Firstly, F9 cDNA was amplified by forward primer
5′-GGGGTACCCCGCCACCATGCAGCGCGTGAACA
TGATC-3′ and reverse primer 5′-CGACGCGTCGT
TAAGTGAGCTTTGTTTTTTCC-3′; then F9 cDNA and
the AAVS1-EF1α-puromycin empty plasmid were digested
by MluI and KpnI endonuclease; the digested products
were then connected by the T4 ligase; and, finally, sequen-
cing was carried out to ensure that no error occurred.
Transfection of HEK293T cells and iPSCs
To test the efficiency of the constructed plasmids,
HEK293T cells were firstly transfected using the Lipofec-
tamine 2000 transfection reagent (Invitrogen). iPSCs
were electroporated with the same plasmids, using the
Lonza Amaxa Human Stem Cell Nucleofector Starter
Kit and program B-016. Forward primer (F1) 5′-
TTCGGGTCACCTCTCACTCC-3′ and reverse primer
(R1) 5′-GGCTCCATCGTAAGCAAACC were used to
detect the full inserted fragment. When insertion failed,
the amplification length was 468 bp; if successful, the
amplification length was 4.9 kb. Forward primer (F2) 5′-
TTCCGCATTGGAGTCGCTTTA-3′ and reverse primer
(R2) 5′-GTGGGCTTGTACTCGGTCATCT-3′ were used
to detect the 5′ junction point of insertion. When inser-
tion failed, nothing could be amplified; if successful, the
amplification length was 1.3 kb. GAPDH was amplified as
internal control for amount of genomic DNA. Forward
primer 5′-ACCCACTCCTCCACCTTT-3′ and reverse
primer 5′-CTCTTGTGCTCTTGCTGGG-3′ were used,
and the amplification length was 283 bp. Forward primer
(F9-F) 5′-TGCTCCTGTACTGAGGGA-3′ and reverse
primer (F9-R) 5′-AATGATTGGGTGCTTTGA-3′ were
used to detect the expression of F9.
Off-target detection of CRISPR-Cas9
Potential off-target sites that differed from the sgRNA
sequence by up to five nucleotides in the genome were
searched using the web-based program Cas-OFFinder
(http://www.rgenome.net/cas-offinder/). After insertion
was detected in iPSCs, genomic DNAs extracted from
the parental iPSCs and the successful inserted iPSCs
were subjected to whole genome sequencing (WGS).
Unique mutations of the inserted iPSCs different from
those in the parental iPSCs were selected. These unique
mutations were compared with the potential off-target
sites to detect whether they overlapped. WGS was carried
out at BGI-Shenzhen (Shenzhen, China), yielding 30×
coverage. Sequencing was performed on the HiSeq X Ten
platform (Illumina, Santiago, CA, USA). Raw image files
were processed by Illumina pipeline for base calling with
default parameters and the sequences of each individual
were generated as 150-bp paired-end reads.
Differentiation of iPSCs into hepatocytes
The differentiation of iPSCs into hepatocytes was carried
out as described previously [23], with some modifica-
tions: 0.5 μM A83–01 and 0.1 μM Compound E were
added during days 11–15.
Characterization of hepatocytic functions
We detected FOXA2, SOX17, and GATA4 on day 5,
hepatocyte nuclear factor 4 alpha (HNF4α) on day 10,
alpha-fetoprotein (AFP) on day 15, and albumin
(ALB) on day 20 by immunofluorescence staining. In
addition, flow cytometry analysis was performed to
detect AFP and ALB according to the provided
protocols. The expressions of AFP, ALB, HNF4α,
tryptophan 2,3-dioxygenase (TDO2), tyrosine-alpha-
testosterone (TAT), and CYP3A4 were detected by
qRT-PCR. The primer sequences are presented in
Additional file 2: Table S2. For Periodic Acid–Schiff
(PAS) staining, after fixation using 4% paraformalde-
hyde, cells were cultured in 1% periodic acid at 37 °C
for 20 min, were dried at 37 °C for 1 h, and then
were cultured in Schiff reagent at 37 °C for 30 min
in the dark. For low-density lipoprotein (LDL) uptake
and LDL-receptor expression, experiments were per-
formed by the protocol provided by the LDL Uptake
Cell-Based Assay Kit (Cayman Chemical). For indocy-
anine green (ICG) uptake, cells were incubated with
ICG (1 mg/ml) in basal medium for 1 h at 37 °C,
and then in fresh medium.
Transplantation of hepatocytes into NOD/SCID mice
Four-week-old NOD/SCID mice were treated with
retrosine (70 mg/kg, 4 weeks and 2 weeks before
transplantation) and carbon tetrachloride (CCl4, 0.5 ml/
kg, 24 h before transplantation). A total of 4.2 × 107/kg
hepatocytes were transplanted through splenic injection.
Plasma samples were collected to detect hFIX antigen
every 2 weeks after transplantation, and mice liver
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tissues were obtained for human ALB detection by
immunohistochemistry according to general protocols.
hFIX antigen assay
The assay of hFIX antigen in cell culture supernatant
and plasma of NOD/SCID mice was carried out using
the human Factor IX ELISA kit (Abcam, Cambridge,
UK) according to the manufacturer’s protocol.
hFIX activity assay
To analyze hFIX activity, Coagulation Factor IX Deficient
Plasma (Siemens, Newark, DE, USA) and an Automatic
Coagulation Analyzer (Sysmex CS-5100; Sysmex Kobe,
Japan) were used to examine the activated partial
thromboplastin time (APTT), which was compared with
the calibration curve of standard plasma for calculating
the hFIX content. The measurement was performed
according to the manufacturer’s instructions, and a refer-
ence curve was constructed using serial dilutions of stand-
ard human plasma (Siemens).
Statistical analysis
Data were presented as mean ± SEM and were com-
pared by Student’s t test. P < 0.05 was considered statis-
tically significant.
Results
Generation of patient-specific iPSCs from PBMNCs
We collected PBMNCs of an 11-year-old male HB pa-
tient from China, with a known F9 gene mutation: c.
676C > T, p.Arg226Trp. As described previously [22],
isolated PBMNCs were cultured in erythroid culture
medium for 6 days, and then transfected with
integration-free episomal plasmids. After 7-day culture
in iPSC generation medium, small iPSC colonies were
observed, which were then cultured in Essential 8
medium (Fig. 1a). When iPSC colonies grew large
enough, cells were removed, cultured in Essential 8
medium on Matrigel-coated plates, and passaged into
small pieces using 0.5 mM EDTA (Fig. 1b). After 10
passages, karyotype and pluripotency detection were
carried out. The karyotype was normal (Fig. 1c), with 22
pairs of autosomes and a pair of sex chromosomes. qRT-
PCR (Fig. 1d) and immunofluorescence staining (Fig.
1e) showed expression of pluripotent markers, includ-
ing OCT4, SOX2, NANOG, TRA-1-60, and SSEA4.
iPSCs produced teratomas containing multiple deriva-
tives of three germ layers after being injected into NOD/
SCID mice (Fig. 1f). The iPSCs were sequenced to ensure
the existence of mutation c.676C > T (Additional file 3:
Figure S1a).
Successful insertion of F9 cDNA into the AAVS1 locus of HEK
293 T cells and HB-iPSCs
In this study, we attempted to insert human full-length
F9 cDNA into the AAVS1 locus to acquire stable expres-
sion of hFIX. Fig. 2a shows the schematic diagram of
CRISPR-Cas9. Firstly, HEK 293 T cells were transfected
to detect the efficiency of the plasmids. Additional file 4:
Table S3 presents the dosages of plasmids and cell
numbers used in the study. We observed that approxi-
mately 80% of cells were GFP-positive 24 h after trans-
fection in the GFP group (Fig. 2b). Forty-eight hours
after transfection, 2 μg/ml puromycin was used for drug
selection in both groups. After three passages, the
remaining cells were assayed for F9 expression in the F9
group. Insertion could be detected using primers F1, R1
and F2, R2 in the 293 T-insertion group (Fig. 2c, d). The
expression of F9 in the 293 T-insertion group was not-
ably higher than that in the 293 T-wildtype (WT) group
(Fig. 2e). hFIX was also detected in the 293 T-insertion
group through immunofluorescence staining (Fig. 2f ).
Collectively, these results demonstrated the efficiency of
the plasmids.
To transfect HB-iPSCs, 1 × 106 iPSCs were treated
with 10 μM ROCK inhibitor Y26732 for 4–6 h. After
electroporation, the iPSCs were seeded onto feeder cells.
Twenty-four hours later, sporadic GFP-positive cells
could be seen in the GFP group. Forty-eight hours after
transfection, 0.3 μg/ml puromycin was used for drug
selection. Most iPSCs died after drug selection, but a
few survived. After about 7 days, each surviving iPSC
colony grew large enough for picking out in both groups
(Fig. 3a, b) for further insertion detection. We picked
out six colonies in total in the F9 group. As shown in
Fig. 3c, using primers F2 and R2, a 1.3-kb fragment
could be detected in all iPSC colonies, indicating the
successful 5′ junction; using primers F1 and R1, 468-bp
and 4.9-kb fragments could be seen in iPSC colonies 1,
2, 3, 4, and 6, indicating heterozygous insertion of F9
cDNA; only a 4.9-kb fragment could be seen in iPSC
colony 5, indicating homozygous insertion of F9 cDNA.
Additional file 3: Figure S1b shows the sequencing result
of F9 mutation (c.676C > T) of colony 5. The karyotype
of iPSC colony 5 was normal and its pluripotency was
well detected (Additional file 5: Figure S2). So, iPSC
colony 5 (referred to as iPSC-insertion) was used for
further hepatocytic differentiation.
Off-target effect detection in the successfully inserted iPSCs
Using Cas-OFFinder, 1799 potential off-target sites that
differed from the sgRNA sequence by up to five nucleo-
tides in the genome were found. We found 97,968 indels,
3084 structural variations (SVs), 51,628 single nucleotide
polymorphisms (SNPs), and 2225 copy number variations
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(CNVs) unique to the inserted iPSCs compared to that in
the parental iPSCs. Since indels and SVs comprise virtually
all of the mutations introduced by CRISPR-Cas9 [24], we
focused solely on indels and SVs. Through comparison of
potential off-target sites, and indels and SVs unique to the
inserted iPSCs, we did not find any overlapping mutation
between them (Additional file 6: Figure S3).
Functional hepatocyte differentiation of inserted iPSCs
When iPSCs acquired a confluence of 50–70%, the
differentiation was performed as shown in Fig. 4a. The
total differentiation process took 20 days, with days
6–15 under 4% O2. Immunofluorescence staining indi-
cated expression of FOXA2, SOX17, and GATA4 on day
5, HNF4α on day 10, AFP on day 15, and ALB on day
20 (Fig. 4b). Flow cytometry analysis indicated that the
expression of AFP and ALB was greater than 90% (Fig.
4c). Then we detected the hepatic markers at the gene
level. qRT-PCR showed the expression of AFP, ALB,
HNF4α, TDO2, and TAT relative to GAPDH (Fig. 4d). It
was interesting to note that the marker of precursor he-
patocytes (AFP) was high, whereas the markers of
Fig. 1 Generation and characterization of patient-specific iPSCs from PBMNCs. a Schematic of patient-specific iPSC generation from PBMNCs. b Small
iPSC-like colonies appeared 7 days after electroporation. At 14 days after electroporation, iPSC colonies grew big enough for picking out. After being
picked out, iPSCs were cultured on Matrigel-coated plates without feeder. c Karyotype of iPSCs was normal. d qRT-PCR analysis showed expression of
OCT4, SOX2, and NANOG of iPSCs (n = 3 independent experiments for each sample). PBMNCs from patient used as negative control, H1 embryonic
stem cells used as positive control. e Immunofluorescence staining showed expression of TRA-1-60, SSEA4, OCT4, and NANOG. f Sections of teratomas
stained with H&E (endoderm: bronchus; mesoderm: cartilage; ectoderm: epidermis). All scale bars represent 100 μm. PBMNC peripheral blood
mononuclear cell, iPSC induced pluripotent cell, D day, GAPDH glyceraldehyde 3-phosphate dehydrogenase, HB hemophilia B
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mature hepatocytes (ALB, TDO2, and TAT) were rela-
tively low, indicating that the differentiated hepatocytes
we obtained were still in the process of further maturing.
Compared to the expression of ALB in flow cytometry
(Fig. 4c), the ALB expression in qRT-PCR (Fig. 4d) was
relatively low, which might be caused by the asynchrony
Fig. 2 CRISPR-Cas9 and insertion of F9 cDNA into AAVS1 locus of HEK293T cells. a Schematic of CRISPR-Cas9. b About 80% of cells were GFP-
positive 24 h after transfection in the GFP group. c Primers F1, R1 were used to detect the full fragment of insertion. In the 293 T-WT group, only
a 468-bp fragment could be seen (yellow arrow); in the 293 T-insertion group, both 468-bp and 4.9-kb fragments could be seen (yellow arrow).
d. Primers F2, R2 used to detect 5′ junction point of insertion. In the 293 T-WT group, nothing could be seen; in the 293 T-insertion group, a 1.3-
kb fragment could be seen (yellow arrow). e qRT-PCR showed F9 expression of the 293 T-insertion group was extremely higher than that in the
293 T-WT group. AAVS1-EF1α-puromycin empty plasmid did not produce any hFIX expression (n = 3 independent experiments for each sample).
f Immunofluorescence staining showed hFIX expression in the 293 T-insertion group. All scale bars represent 100 μm. CRISPR-Cas9 clustered
regularly interspaced short palindromic repeats-CRISPR associated nuclease 9, WT wildtype, GAPDH glyceraldehyde 3-phosphate dehydrogenase,
DAPI 4′,6-diamidino-2-phenylindole, HFIX human factor IX
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of gene transcription and protein translation. Then
we compared the expression of pluripotent markers
(OCT4, SOX2, and NANOG) and hepatic markers
(AFP, ALB, HNF4α, TDO2, TAT, and CYP3A4) be-
tween the undifferentiated iPSCs and the differenti-
ated hepatocytes (referred to as iPSC-insertion-Heps)
by qRT-PCR (Fig. 4e). After differentiation, the ex-
pression of pluripotent markers decreased, whereas
the expression of hepatic markers increased. The
differentiated cells had the function of glycogen stor-
age (Additional file 7: Figure S4a) and ICG uptake
(Additional file 7: Figure S4b). The differentiated cells
also expressed LDL-receptor (Additional file 7: Figure
S4c) and had the ability for LDL uptake (Additional
file 7: Figure S4d).
F9 expression, and hFIX antigen levels and activity in the
supernatant medium
We compared F9 expression between iPSC-insertion-
Heps and differentiated hepatocytes from the patient’s
uninserted iPSCs (referred to as iPSC-parental-Heps)
by qRT-PCR (Fig. 5a). qRT-PCR indicated that F9
expression in iPSC-insertion-Heps was notably higher
than that in the other two groups. hFIX antigen in
cell culture supernatant of iPSC-insertion-Heps was
higher than that in iPSC-parental-Heps (44.357 ± 4.
035 ng/ml vs 1.575 ± 0.004 ng/ml, P < 0.0001) (Fig.
5b) at the end of the 20th day. hFIX activity in cell
culture supernatant of iPSC-insertion-Heps was also
higher than that in iPSC-parental-Heps (5.038 ± 0.
296% vs 1.725 ± 0.103%, P = 0.0084) (Fig. 5c).
Fig. 3 Insertion of F9 cDNA into AAVS1 locus of HB iPSCs. a Surviving cells grew large in the GFP group after puromycin selection. b Surviving
cells (colony 5) grew large in the F9 group after puromycin selection. c Primers F2, R2 used to detect 5′ junction point of insertion. A 1.3-kb
fragment could be seen in all iPSC colonies; primers F1, R1 used to detect the full fragment of insertion. The 468-bp and 4.9-kb fragments could
be seen in iPSC colonies 1, 2, 3, 4 and 6; while only a 4.9-kb fragment could be seen in iPSC colony 5, there was no 468-bp fragment. GAPDH
was amplified as internal control of amount of genomic DNA. A 283-bp fragment of same intensity could be seen in all iPSC colonies. All scale
bars represent 100 μm. iPSC induced pluripotent cell, GAPDH glyceraldehyde 3-phosphate dehydrogenase
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Fig. 4 Differentiation of iPSCs into hepatocytes and characterization of hepatocytic functions. a Schematic showing stepwise protocol for producing
hepatocytes from iPSCs. b Immunofluorescence staining showed expression of SOX17, FOXA2, and GATA4 on day 5, HNF4α on day 10, AFP on day 15,
and ALB on day 20. c Flow cytometry analysis showed expression of AFP and ALB > 90%. d qRT-PCR showed relative expression of HNF4α, AFP, ALB,
TDO2, and TAT relative to GAPDH (n = 3 independent experiments for each sample). e Expression of pluripotent markers (OCT4, SOX2, and NANOG) and
hepatic markers (AFP, ALB, HNF4α, TAT, TDO2, and CYP3A4) between iPSC-insertion and iPSC-insertion-Heps compared by qRT-PCR (n = 3 independent
experiments for each sample). After differentiation, expression of pluripotent markers decreased, while expression of hepatic markers increased. All scale
bars represent 100 μm. BMP bone morphogenetic protein, bFGF basic fibroblast growth factor, iPSC induced pluripotent cell, HGF, hepatocyte growth
factor, DAPI 4′,6-diamidino-2-phenylindole, AFP alpha-fetoprotein, ALB albumin, GAPDH glyceraldehyde 3-phosphate dehydrogenase
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Implanting ability of the differentiated hepatocytes
Fifteen NOD/SCID mice were divided randomly into
three equal groups. iPSC-insertion-Heps were injected
into the first group, iPSC-parental-Heps were injected
into the second group, and 100 μl basic Hepatocyte
Culture medium (Lonza) was injected into the third
group as control. Two weeks after transplantation, only
one mouse in the iPSC-parental-Heps group died, and
all of the others survived. We detected hFIX antigen in
mice plasma by ELISA (Fig. 5d). hFIX antigen levels in
the iPSC-insertion-Heps group was higher than that in
the iPSC-parental-Heps group (4.998 ± 1.703 ng/ml vs 1.
178 ± 0.076 ng/ml, P = 0.0159) and in the control group
(4.998 ± 3.808 ng/ml vs 0.789 ± 0.003 ng/ml, P = 0.
0079). hFIX antigen levels in the iPSC-parental-Heps
group was higher than that in the control group (1.178 ±
0.076 ng/ml vs 0.789 ± 0.003 ng/ml, P = 0.0159). We then
detected human ALB in four mice of the iPSC-insertion-
Heps group by immunohistochemistry (Fig. 5e).
Discussion
iPSCs possess self-renewal ability and multilineage dif-
ferentiation potential similar to embryonic stem cells,
and are not constrained by traditional ethical issues,
providing potentially revolutionary approaches in per-
sonalized cell therapy, disease modeling, and drug
screening [25, 26]. Conventionally, human iPSCs were
generated from skin fibroblasts. Being a hemorrhagic
disease, hemophilia is not suitable for this invasive op-
eration. As a result, previous studies generated iPSCs of
hemophilia patients from urine cells [27–29]. PBMNCs
have been reported as the best cell source for cell
reprogramming owing to their better quality, quantity,
Fig. 5 Comparison of F9 expression, and hFIX antigen levels and activity between iPSC-parental-Heps and iPSC-insertion-Heps. a qRT-PCR showed F9
expression in undifferentiated iPSCs, iPSC-parental-Heps, and iPSC-insertion-Heps (n = 3 independent experiments for each sample). b Comparison of hFIX
antigen levels in cell culture supernatant between iPSC-parental-Heps and iPSC-insertion-Heps. Student’s t test used. Data shown are mean ± SEM (n = 8 in
iPSC-parental-Heps group, n = 9 in iPSC-insertion-Heps group). c Comparison of hFIX activity in cell culture supernatant between iPSC-parental-Heps and
iPSC-insertion-Heps. Student’s t test used. Data shown are mean ± SEM (n = 4 in iPSC-parental-Heps group, n = 8 in iPSC-insertion-Heps group). d Two
weeks after transplantation, hFIX antigen levels in mice plasma of the iPSC-insertion-Heps group, iPSC-parental-Heps group, and control group detected by
ELISA. Student’s t test used. Data shown are mean ± SEM (n = 5 in iPSC-insertion-Heps group and the control group, n = 4 in iPSC-parental-Heps group). e
Two weeks after transplantation, human ALB was detected in mice #1, #2, #4, and #5 of the iPSC-insertion-Heps group by immunohistochemistry. All scale
bars represent 50 μm. GAPDH glyceraldehyde 3-phosphate dehydrogenase, iPSC induced pluripotent cell, hFIX human factor IX, DAPI 4′,6-diamidino-2-
phenylindole, ALB albumin
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and easy accessibility [30–34]. Therefore, we generated
iPSCs of HB patients from PBMNCs in this study.
The development of genetic engineering tools opens
up many opportunities for the treatment of human
hereditary diseases. Notably, the CRISPR-Cas9 system is
the most powerful homologous recombination-based
gene editing method, and has been used in human stud-
ies of beta-thalassemia, cystic fibrosis, and sickle cell dis-
ease [35–38]. CRISPR-Cas9 has been used in hemophilia
to correct structural variations and chromosomal inver-
sions of HA patients [29, 39] and somatic mutations of
HB mice [40]. A previous study suggested that GC-rich
sgRNAs improved targeting efficiency, whereas poly(U)
stretches close to the protospacer-adjacent motif (PAM)
sequence were associated with sgRNAs of lower effi-
ciency [41]. When designing sgRNAs for in-situ correc-
tion, one has to constrain the sgRNA sequences around
the mutant nucleotides, which runs the risk of con-
structing sgRNAs with lower targeting efficiency. In this
study, we used a sgRNA with high efficiency to target
the AAVS1 locus and a donor plasmid carrying human
full-length F9 cDNA, and then these plasmids could be
applied to all HB patients regardless of their mutation
type, eliminating the trouble of constructing sgRNAs
with lower targeting efficiency. This approach is particu-
larly suitable for HA, as there are already 2015 different
mutations documented in the Factor VIII Gene (F8)
Variant Database (http://www.factorviii-db.org/) [42],
which makes it quite difficult to generate sgRNAs with
high efficiency when performing in-situ correction.
Thus, in our future studies we will aim to knock-in
human full-length F8 cDNA or B domain-deleted (BDD)
F8 cDNA into the AAVS1 locus of iPSCs from HA
patients.
Before transfecting the iPSCs, HEK293T cells were
transfected firstly to test the knock-in efficiency of
plasmids. HEK293T cells are used to check the cut-
ting efficiency of sgRNAs generally [43], because
HEK293T cells are easy to transfect. But the epige-
nome state and genome sequences of HEK293T cells
are different from primary hepatocytes. High effi-
ciency of sgRNAs in HEK293T cells does not mean
high efficiency in primary hepatocytes. So primary he-
patocytes with F9 mutation or a F9 knockout trans-
formed cell line were better choices to detect the
effect of plasmids in our further study.
A problem that cannot be ignored in CRISPR-Cas9
is off-target effects. Previous studies have shown that
mismatches with 20 nucleotides of sgRNAs can be
tolerated, leading to genome editing at undesired sites
[44–47]. However, the off-target incidence is lower in
pluripotent stem cells (PSCs) [24, 29, 43], which is
consistent with lower knock-out and knock-in effi-
ciency of sgRNAs in PSCs [48]. CRISPR-Cas9 can
induce mutations at sites that differ by as many as
five nucleotides from the intended 20 nucleotides
[44]. Therefore, in this study, we compared potential
off-target sites that differed from the sgRNA sequence
by up to five nucleotides in the genome with indels
and SVs unique to the inserted iPSCs, and found no
overlapping mutations. As a result, no off-target mu-
tations were found in our study.
In our research, hepatocytes differentiated from hu-
man iPSCs should be transplanted to immunodefi-
cient mice or hemophilia mice treated with immune-
suppression drugs. Since there are no immunodefi-
cient hemophilic mice models available, we trans-
planted the differentiated hepatocytes into NOD/SCID
mice instead. The Automatic Coagulation Analyzer
(Sysmex CS-5100) we used to detect the hFIX activity
could not distinguish between human FIX and mouse
FIX, so we did not detect hFIX activity, but instead
assayed the hFIX antigen by ELISA. hFIX antigen
could be detected only 2 weeks after transplantation,
and could no longer be detected after 4 weeks or
later in all the groups. It was possible that newly re-
generated mice hepatocytes rejected the transplanted
human hepatocytes. Better ways to improve implant-
ing efficiency should be further explored. Considering
that human and NOD/SCID mice are two different
species, human cells cannot transplant into NOD/
SCID mice thoroughly. So it may make sense that the
FIX levels in mice plasma seem to be much lower in
our research. However, the situation may be com-
pletely different when human cells are retransfused
into the human body where they came from, because
there is no immunological rejection.
Conclusions
We generated HB patient-specific iPSCs from PBMNCs
with normal karyotype and good pluripotency. PBMNCs
are better somatic cell choices for generating iPSCs from
hemophilia patients. Although the efficiency of CRISPR-
Cas9 in PSCs is relatively low, we successfully knocked
the human full-length F9 cDNA into the AAVS1 locus
of the iPSCs without off-target effects. Therefore, it is of
far-reaching significance to construct sgRNAs with high
efficiency, especially when they are used in PSCs. In
addition, CRISPR-Cas9 is relatively safe to be used in
PSCs, considering the low off-target effects. The differ-
entiated hepatocytes from inserted iPSCs could secrete
hFIX stably and were able to be transplanted into the
NOD/SCID mice in the short term, which showed great
promise for further exploration of in-vivo research. In
summary, by combining the iPSC technique with the
CRISPR-Cas9 system, we provide a new approach for
clinical gene therapy for hemophilia.
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